JP2023523096A - 急性呼吸促迫症候群を治療するための組成物および方法 - Google Patents

急性呼吸促迫症候群を治療するための組成物および方法 Download PDF

Info

Publication number
JP2023523096A
JP2023523096A JP2023506362A JP2023506362A JP2023523096A JP 2023523096 A JP2023523096 A JP 2023523096A JP 2023506362 A JP2023506362 A JP 2023506362A JP 2023506362 A JP2023506362 A JP 2023506362A JP 2023523096 A JP2023523096 A JP 2023523096A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antibody
sequence seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023506362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523096A5 (https=
Inventor
マイケル ジョン ブルックス
ブレア リチャード ジョージ ゴードン
パーディープ ニジャワン
Original Assignee
エデサ バイオテック リサーチ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エデサ バイオテック リサーチ インコーポレイテッド filed Critical エデサ バイオテック リサーチ インコーポレイテッド
Publication of JP2023523096A publication Critical patent/JP2023523096A/ja
Publication of JP2023523096A5 publication Critical patent/JP2023523096A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023506362A 2020-04-20 2021-04-20 急性呼吸促迫症候群を治療するための組成物および方法 Pending JP2023523096A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063012786P 2020-04-20 2020-04-20
US202063012783P 2020-04-20 2020-04-20
US63/012,783 2020-04-20
US63/012,786 2020-04-20
US202063081662P 2020-09-22 2020-09-22
US63/081,662 2020-09-22
PCT/CA2021/050544 WO2021212222A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Publications (2)

Publication Number Publication Date
JP2023523096A true JP2023523096A (ja) 2023-06-01
JP2023523096A5 JP2023523096A5 (https=) 2024-04-25

Family

ID=78270861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506362A Pending JP2023523096A (ja) 2020-04-20 2021-04-20 急性呼吸促迫症候群を治療するための組成物および方法

Country Status (8)

Country Link
US (1) US20230192881A1 (https=)
EP (1) EP4138912A4 (https=)
JP (1) JP2023523096A (https=)
CN (1) CN115697410A (https=)
AU (1) AU2021261060A1 (https=)
CA (1) CA3174429A1 (https=)
IL (1) IL297363A (https=)
WO (1) WO2021212222A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020149518A1 (ko) * 2019-01-14 2020-07-23 주식회사 에이아이인사이트 안저영상 자동판독을 위한 딥러닝 아키텍처 시스템 및 딥러닝 아키텍쳐 시스템을 이용한 안저영상 자동판독 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539925A (ja) * 2013-10-22 2016-12-22 ノビミューン エスアー Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
JP2010526868A (ja) * 2007-05-14 2010-08-05 ノビミューン エスアー 改変されたエフェクター機能を有するＦｃ受容体結合ポリペプチド
US8734790B2 (en) * 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
CA3037961A1 (en) * 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539925A (ja) * 2013-10-22 2016-12-22 ノビミューン エスアー Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTIMICROB. AGENTS CHEMOTHER., vol. 64(5), JPN6025017321, 21 April 2020 (2020-04-21), pages 00399 - 20, ISSN: 0005784445 *
CELL, vol. 133(2), JPN6025017317, 2008, pages 235 - 249, ISSN: 0005784441 *
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 101(2), JPN6026003218, 2017, pages 200 - 208, ISSN: 0005784443 *
EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 15, JPN6026003215, 2018, pages 3376 - 3384, ISSN: 0005784442 *
MUCOSAL IMMUNOL., vol. 9(5), JPN6025017320, 2016, pages 1173 - 1182, ISSN: 0005784444 *

Also Published As

Publication number Publication date
EP4138912A4 (en) 2024-08-07
CA3174429A1 (en) 2021-10-28
WO2021212222A1 (en) 2021-10-28
CN115697410A (zh) 2023-02-03
IL297363A (en) 2022-12-01
EP4138912A1 (en) 2023-03-01
AU2021261060A1 (en) 2022-11-17
US20230192881A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP7351989B2 (ja) 炎症性状態の処置方法
JP7486415B2 (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
JP6858182B2 (ja) インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用
WO2021202563A1 (en) Methods of treating coronavirus infection
RU2595836C2 (ru) Способы введения антагонистов интегрина бета7
JP2023159169A (ja) 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
US20170029498A1 (en) Uses of a dual v region antibody-like protein
US20230416344A1 (en) Methods for treating a complement mediated disorder caused by viruses
EP2782599B1 (en) Administration of alpha4beta7 hetero-dimer-specific antibody
US10689441B2 (en) Anti—TLR4 antibodies and methods of use thereof
KR20170020519A (ko) 항―ｉｌ４―ｉｌ１３ ２특이성 항체
JP2023523096A (ja) 急性呼吸促迫症候群を治療するための組成物および方法
US12583929B2 (en) Method of treating acute respiratory distress syndrome
JP6882440B2 (ja) 抗ｉｌ４−ｉｌ１３二重特異性抗体
US20230365712A1 (en) Notch4 antibodies and uses thereof
AU2023229284A1 (en) Methods and compositions for treating and preventing fibrosis
WO2025217677A1 (en) Methods for treating neutrophilic skin conditions
CN116670165A (zh) SARS-CoV-2受体结合结构域的特异性抗体及治疗方法
HK1245666A1 (en) Compositions comprising a dual v region antibody-like protein
HK1245666B (en) Compositions comprising a dual v region antibody-like protein
EA051460B1 (ru) Способы лечения воспалительных состояний

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260424